Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-17-3668. [Epub ahead of print]

PMID:
30082477
2.

Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer.

Venigalla S, Chowdhry AK, Wojcieszynski AP, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E, Mahmoud NN, Reiss KA, Shabason JE.

Clin Colorectal Cancer. 2018 Sep;17(3):e557-e568. doi: 10.1016/j.clcc.2018.05.005. Epub 2018 May 17.

PMID:
29910004
3.

A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.

Margalit O, Mamtani R, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Eur J Cancer. 2018 Jun;96:105-110. doi: 10.1016/j.ejca.2018.03.022. Epub 2018 Apr 24.

PMID:
29698932
4.

Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity.

Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, Hsu C, Levine M, Mondschein J, Nadolski G, Olthoff K, Reiss KA, Rosen M, Siegelman E, Metz JM, Ben-Josef E.

Am J Clin Oncol. 2018 Mar 16. doi: 10.1097/COC.0000000000000435. [Epub ahead of print]

PMID:
29553972
5.

Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.

Margalit O, Mamtani R, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Eur J Cancer. 2018 May;94:1-5. doi: 10.1016/j.ejca.2018.01.112. Epub 2018 Mar 20.

PMID:
29502035
6.

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.

Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.

Cancer Chemother Pharmacol. 2018 Mar;81(3):609-614. doi: 10.1007/s00280-018-3519-6. Epub 2018 Jan 23.

PMID:
29362902
7.

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.

Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE.

J Clin Oncol. 2017 Nov 1;35(31):3575-3581. doi: 10.1200/JCO.2017.73.8245. Epub 2017 Sep 5.

PMID:
28872925
8.

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS.

Gynecol Oncol. 2017 Mar;144(3):486-490. doi: 10.1016/j.ygyno.2017.01.016. Epub 2017 Jan 18.

9.

Immune Control Despite Protracted Lymphopenia After Chemoradiation in an Elite Controller.

Reiss KA, Jackson DC, Piotrowski A, Grossman S, Blankson JN.

Open Forum Infect Dis. 2016 Jan 29;3(1):ofw016. doi: 10.1093/ofid/ofw016. eCollection 2016 Jan.

10.

Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship.

Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R.

J Cancer Educ. 2017 Sep;32(3):496-502. doi: 10.1007/s13187-015-0974-1.

PMID:
26768145
11.

Immune Therapy in GI Malignancies: A Review.

Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D.

J Clin Oncol. 2015 Jun 1;33(16):1745-53. doi: 10.1200/JCO.2015.60.7879. Epub 2015 Apr 27. Review.

12.

The sadness connection.

Reiss KA.

Int J Psychiatry Med. 2015;49(2):162-4. doi: 10.1177/0091217415572109. Epub 2015 Mar 10. No abstract available.

PMID:
25757848
13.

A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.

Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Siu LL, Azad NS.

Clin Cancer Res. 2015 Jan 1;21(1):68-76. doi: 10.1158/1078-0432.CCR-14-1552. Epub 2014 Oct 29.

14.

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Reiss KA, Forde PM, Brahmer JR.

Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Review.

15.

What lies within: novel strategies in immunotherapy for non-small cell lung cancer.

Forde PM, Reiss KA, Zeidan AM, Brahmer JR.

Oncologist. 2013;18(11):1203-13. doi: 10.1634/theoncologist.2013-0171. Epub 2013 Oct 8. Review.

16.

Healthy, but comatose.

Houston B, Reiss KA, Merlo C.

Am J Med. 2011 Apr;124(4):303-5. doi: 10.1016/j.amjmed.2010.12.002. No abstract available.

PMID:
21435419
17.

Raltegravir-induced cerebellar ataxia.

Reiss KA, Bailey JR, Pham PA, Gallant JE.

AIDS. 2010 Nov 13;24(17):2757. doi: 10.1097/QAD.0b013e32833fca42. No abstract available.

PMID:
20980871
18.

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.

Ge R, Rajeev V, Subramanian G, Reiss KA, Liu D, Higgins L, Joly A, Dugar S, Chakravarty J, Henson M, McEnroe G, Schreiner G, Reiss M.

Biochem Pharmacol. 2004 Jul 1;68(1):41-50.

PMID:
15183116

Supplemental Content

Loading ...
Support Center